The original success of the copyright undeniably revolutionized the pharmaceutical landscape, but investing in companies primarily reliant on off-patent versions presents a complex picture. Despite early returns were impressive, the cessation of patents and the emergence of less expensive alternatives have eroded market share. Therefore, a thorough